PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced key appointments across its leadership team. These include:
Originally posted here:
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
Related Post
- Shattuck Labs Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights - March 1st, 2024
- Gritstone bio Announces Workforce Reduction - March 1st, 2024
- Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - March 1st, 2024
- Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results - March 1st, 2024
- ProKidney to Participate in Jefferies Biotech on the Bay Summit - March 1st, 2024
- Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance - March 1st, 2024
- Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004) - March 1st, 2024
- Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates - March 1st, 2024
- Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook - March 1st, 2024
- Prelude Therapeutics to Participate in Barclays Global Healthcare Conference - March 1st, 2024
- Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC - March 1st, 2024
- Certara Reports Fourth Quarter 2023 Financial Results - March 1st, 2024
- Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update - March 1st, 2024
- Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference - March 1st, 2024
- GENFIT Announces Revenues and Cash Position as of December 31, 2023 - March 1st, 2024
- Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau - March 1st, 2024
- Nephros Schedules Conference Call for Fourth Quarter and Fiscal Year 2023 Financial Results - March 1st, 2024
- Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results - March 1st, 2024
- Spectral AI Appoints Peter M. Carlson as CEO - March 1st, 2024
- Arcutis to Present at the TD Cowen 44th Annual Health Care Conference - March 1st, 2024
- Scilex Holding Company Announces Publication in Anesthesiology Journal of Results from an Investigator-Initiated Research Study Using ZTlido® for the... - February 21st, 2024
- PharmAla Data to be Published in ACS Chemical Neuroscience - February 21st, 2024
- ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge... - February 21st, 2024
- AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation - February 21st, 2024
- Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting - February 21st, 2024
- Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference - February 21st, 2024
- Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00... - February 21st, 2024
- SOPHiA GENETICS to Announce Financial Results for the Fourth Quarter and Full-Year 2023 on March 5, 2024 - February 21st, 2024
- NGM Bio to Participate in the Cowen 44th Annual Health Care Conference - February 21st, 2024
- NurExone’s Intellectual Property Portfolio Expands - February 21st, 2024
- PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market - February 21st, 2024
- Arvinas Announces Chief Financial Officer Transition - February 21st, 2024
- Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - February 21st, 2024
- DBV Technologies to Participate in Upcoming AAAAI 2024 Congress - February 21st, 2024
- Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024 - February 21st, 2024
- Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq. - February 21st, 2024
- Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 - February 21st, 2024
- PolTREG appoints Dan Shelly as Chief Business Development Officer - February 21st, 2024
- Sanofi: Information concerning the total number of voting rights and shares - January 2024 - February 21st, 2024
- Bavarian Nordic delivered record financial results in 2023 - February 21st, 2024
- Vistin Pharma ASA: Dividend of NOK 0.75 per share - January 14th, 2024
- HUTCHMED Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status - January 14th, 2024
- Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31... - January 14th, 2024
- Key information relating to the cash dividend to be paid by Vistin Pharma ASA - January 14th, 2024
- QIAGEN N.V. to release results for Q4 2023 and hold webcast - January 14th, 2024
- Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries - January 14th, 2024
- TransCode Therapeutics Announces 1-for-40 Reverse Stock Split - January 14th, 2024
- Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference - January 14th, 2024
- Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference - January 14th, 2024
- Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference - January 14th, 2024
- Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study - January 14th, 2024
- Recommendation by the Orion Nomination Committee on the proposals to be submitted to the 2024 Annual General Meeting - January 14th, 2024
- Boehringer expands production site in Greece for new medicine - January 14th, 2024
- FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to... - January 14th, 2024
- Voting Rights and Shares Capital of the Company - January 14th, 2024
- Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom - January 14th, 2024
- CytomX Therapeutics to Present at the B. Riley Securities Virtual Annual Oncology Conference - January 14th, 2024
- TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO - January 14th, 2024
- Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole - January 14th, 2024
- Medicenna Announces Appointment of New Auditor - January 14th, 2024
- Axial Therapeutics to Present at Upcoming Conferences - January 6th, 2024
- NurExone Announces Closing of a Private Placement for Gross Proceeds of Approximately CAD$2 Million - January 6th, 2024
- Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea - January 6th, 2024
- SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference,... - January 6th, 2024
- Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones - January 6th, 2024
- Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T... - January 6th, 2024
- Cassava Sciences Completes Dividend Distribution of Warrants to Shareholders - January 6th, 2024
- Kriya Announces Gene Therapy Program for Thyroid Eye Disease - January 6th, 2024
- Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in Indianapolis - January 6th, 2024
- Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024 - January 6th, 2024
- OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024 - January 6th, 2024
- Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital - January 6th, 2024
- ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD) - January 6th, 2024
- BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to... - January 6th, 2024
- Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones - January 6th, 2024
- Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program - January 6th, 2024
- Regeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024 - January 6th, 2024
- Societal CDMO Reports Inducement Grants for New Staff - January 6th, 2024
- Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - January 6th, 2024
- Shockwave Medical Reports First Quarter 2023 Financial Results - May 9th, 2023
